H. R. 4771 
One Hundred Thirteenth Congress 
of the 
United States of America 
AT THE SECOND SESSION 
Begun and held at the City of Washington on Friday, 
the third day of January, two thousand and fourteen 
An Act 
To amend the Controlled Substances Act to more effectively regulate anabolic 
steroids. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Designer Anabolic Steroid Control 
Act of 2014’’. 
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT. 
(a) DEFINITIONS.—Section 102(41) of the Controlled Substances 
Act (21 U.S.C. 802(41)) is amended— 
(1) in subparagraph (A)— 
(A) in clause (xlix), by striking ‘‘and’’ at the end; 
(B) by redesignating clause (xlx) as clause (lxxv); and 
(C) by inserting after clause (xlix) the following: 
‘‘(l) 5α-Androstan-3,6,17-trione; 
‘‘(li) 6-bromo-androstan-3,17-dione; 
‘‘(lii) 6-bromo-androsta-1,4-diene-3,17-dione; 
‘‘(liii) 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol; 
‘‘(liv) 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol; 
‘‘(lv) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one; 
‘‘(lvi) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11- 
dione; 
‘‘(lvii) 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol; 
‘‘(lviii) 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one; 
‘‘(lix) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one; 
‘‘(lx) 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol; 
‘‘(lxi) [3,2-c]-furazan-5α-androstan-17β-ol; 
‘‘(lxii) 3β-hydroxy-estra-4,9,11-trien-17-one; 
‘‘(lxiii) 17α-methyl-androst-2-ene-3,17β-diol; 
‘‘(lxiv) 17α-methyl-androsta-1,4-diene-3,17β-diol; 
‘‘(lxv) Estra-4,9,11-triene-3,17-dione; 
‘‘(lxvi) 18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one; 
‘‘(lxvii) 6α-Methyl-androst-4-ene-3,17-dione; 
‘‘(lxviii) 17α-Methyl-androstan-3-hydroxyimine-17β-ol; 
‘‘(lxix) 17α-Methyl-5α-androstan-17β-ol; 
‘‘(lxx) 17β-Hydroxy-androstano[2,3-d]isoxazole; 
‘‘(lxxi) 17β-Hydroxy-androstano[3,2-c]isoxazole; 
‘‘(lxxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole- 
5α-androstan-17β-ol; 
‘‘(lxxiii) [3,2-c]pyrazole-androst-4-en-17β-ol; 
‘‘(lxxiv) [3,2-c]pyrazole-5α-androstan-17β-ol; and’’; and 
(2) by adding at the end the following:
H. R. 4771—2 
‘‘(C)(i) Subject to clause (ii), a drug or hormonal substance 
(other 
than 
estrogens, 
progestins, 
corticosteroids, 
and 
dehydroepiandrosterone) that is not listed in subparagraph (A) and 
is derived from, or has a chemical structure substantially similar 
to, 1 or more anabolic steroids listed in subparagraph (A) shall 
be considered to be an anabolic steroid for purposes of this Act 
if— 
‘‘(I) the drug or substance has been created or manufac-
tured with the intent of producing a drug or other substance 
that either— 
‘‘(aa) promotes muscle growth; or 
‘‘(bb) otherwise causes a pharmacological effect similar 
to that of testosterone; or 
‘‘(II) the drug or substance has been, or is intended to 
be, marketed or otherwise promoted in any manner suggesting 
that consuming it will promote muscle growth or any other 
pharmacological effect similar to that of testosterone. 
‘‘(ii) A substance shall not be considered to be a drug or hor-
monal substance for purposes of this subparagraph if it— 
‘‘(I) is— 
‘‘(aa) an herb or other botanical; 
‘‘(bb) a concentrate, metabolite, or extract of, or a con-
stituent isolated directly from, an herb or other botanical; 
or 
‘‘(cc) a combination of 2 or more substances described 
in item (aa) or (bb); 
‘‘(II) is a dietary ingredient for purposes of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); and 
‘‘(III) is not anabolic or androgenic. 
‘‘(iii) In accordance with section 515(a), any person claiming 
the benefit of an exemption or exception under clause (ii) shall 
bear the burden of going forward with the evidence with respect 
to such exemption or exception.’’. 
(b) CLASSIFICATION AUTHORITY.—Section 201 of the Controlled 
Substances Act (21 U.S.C. 811) is amended by adding at the end 
the following: 
‘‘(i) TEMPORARY
AND PERMANENT SCHEDULING
OF RECENTLY 
EMERGED ANABOLIC STEROIDS.— 
‘‘(1) The Attorney General may issue a temporary order 
adding a drug or other substance to the definition of anabolic 
steroids if the Attorney General finds that— 
‘‘(A) the drug or other substance satisfies the criteria 
for being considered an anabolic steroid under section 
102(41) but is not listed in that section or by regulation 
of the Attorney General as being an anabolic steroid; and 
‘‘(B) adding such drug or other substance to the defini-
tion of anabolic steroids will assist in preventing abuse 
or misuse of the drug or other substance. 
‘‘(2) An order issued under paragraph (1) shall not take 
effect until 30 days after the date of the publication by the 
Attorney General of a notice in the Federal Register of the 
intention to issue such order and the grounds upon which 
such order is to be issued. The order shall expire not later 
than 24 months after the date it becomes effective, except 
that the Attorney General may, during the pendency of pro-
ceedings under paragraph (6), extend the temporary scheduling 
order for up to 6 months.
H. R. 4771—3 
‘‘(3) The Attorney General shall transmit notice of an order 
proposed to be issued under paragraph (1) to the Secretary 
of Health and Human Services. In issuing an order under 
paragraph (1), the Attorney General shall take into consider-
ation any comments submitted by the Secretary in response 
to a notice transmitted pursuant to this paragraph. 
‘‘(4) A temporary scheduling order issued under paragraph 
(1) shall be vacated upon the issuance of a permanent sched-
uling order under paragraph (6). 
‘‘(5) An order issued under paragraph (1) is not subject 
to judicial review. 
‘‘(6) The Attorney General may, by rule, issue a permanent 
order adding a drug or other substance to the definition of 
anabolic steroids if such drug or other substance satisfies the 
criteria for being considered an anabolic steroid under section 
102(41). Such rulemaking may be commenced simultaneously 
with the issuance of the temporary order issued under para-
graph (1).’’. 
SEC. 3. LABELING REQUIREMENTS. 
(a) IN GENERAL.—Section 305 of the Controlled Substances 
Act (21 U.S.C. 825) is amended by adding at the end the following: 
‘‘(e) FALSE LABELING OF ANABOLIC STEROIDS.— 
‘‘(1) It shall be unlawful to import, export, manufacture, 
distribute, dispense, or possess with intent to manufacture, 
distribute, or dispense, an anabolic steroid or product con-
taining an anabolic steroid, unless the steroid or product bears 
a label clearly identifying an anabolic steroid or product con-
taining an anabolic steroid by the nomenclature used by the 
International Union of Pure and Applied Chemistry (IUPAC). 
‘‘(2)(A) A product described in subparagraph (B) is exempt 
from the International Union of Pure and Applied Chemistry 
nomenclature requirement of this subsection if such product 
is labeled in the manner required under the Federal Food, 
Drug, and Cosmetic Act. 
‘‘(B) A product is described in this subparagraph if the 
product— 
‘‘(i) is the subject of an approved application as 
described in section 505(b) or (j) of the Federal Food, Drug, 
and Cosmetic Act; or 
‘‘(ii) is exempt from the provisions of section 505 of 
such Act relating to new drugs because— 
‘‘(I) it is intended solely for investigational use 
as described in section 505(i) of such Act; and 
‘‘(II) such product is being used exclusively for 
purposes of a clinical trial that is the subject of an 
effective investigational new drug application.’’. 
(b) CLARIFICATION TO IMPORT AND EXPORT STATUTE.—Section 
1010 of the Controlled Substances Import and Export Act (21 U.S.C. 
960) is amended, in subsection (a)(1), by inserting ‘‘305,’’ before 
‘‘1002’’. 
(c) CIVIL PENALTIES.—Section 402 of the Controlled Substances 
Act (21 U.S.C. 842) is amended— 
(1) in subsection (a)— 
(A) in paragraph (14), by striking ‘‘or’’ at the end; 
(B) in paragraph (15), by striking the period at the 
end and inserting ‘‘; or’’; and
H. R. 4771—4 
(C) by inserting, after paragraph (15), the following: 
‘‘(16) to violate subsection (e) of section 825 of this title.’’; 
and 
(2) in subsection (c)(1)— 
(A) by inserting, in subparagraph (A), after ‘‘subpara-
graph (B)’’ the following: ‘‘, (C), or (D)’’; and 
(B) by inserting after subparagraph (B) the following: 
‘‘(C) In the case of a violation of paragraph (16) of subsection 
(a) of this section by an importer, exporter, manufacturer, or dis-
tributor (other than as provided in subparagraph (D)), up to 
$500,000 per violation. For purposes of this subparagraph, a viola-
tion is defined as each instance of importation, exportation, manu-
facturing, distribution, or possession with intent to manufacture 
or distribute, in violation of paragraph (16) of subsection (a). 
‘‘(D) In the case of a distribution, dispensing, or possession 
with intent to distribute or dispense in violation of paragraph 
(16) of subsection (a) of this section at the retail level, up to 
$1000 per violation. For purposes of this paragraph, the term ‘at 
the retail level’ refers to products sold, or held for sale, directly 
to the consumer for personal use. Each package, container or other 
separate unit containing an anabolic steroid that is distributed, 
dispensed, or possessed with intent to distribute or dispense at 
the retail level in violation of such paragraph (16) of subsection 
(a) shall be considered a separate violation.’’. 
SEC. 4. IDENTIFICATION AND PUBLICATION OF LIST OF PRODUCTS 
CONTAINING ANABOLIC STEROIDS. 
(a) IN GENERAL.—The Attorney General may, in the Attorney 
General’s discretion, collect data and analyze products to determine 
whether they contain anabolic steroids and are properly labeled 
in accordance with this Act and the amendments made by this 
Act. The Attorney General may publish in the Federal Register 
or on the website of the Drug Enforcement Administration a list 
of products which the Attorney General has determined, based 
on substantial evidence, contain an anabolic steroid and are not 
labeled in accordance with this Act and the amendments made 
by this Act.